M

MannKind Corp
D

MNKD

4.05000
USD
-0.03
(-0.61%)
مغلق
حجم التداول
76,211
الربح لكل سهم
0
العائد الربحي
-
P/E
41
حجم السوق
1,230,928,051
أصول ذات صلة
NEOUSD
NEOUSD
0.16789
(2.53%)
6.75205 USD
C
CYCC
-0.760
(-4.54%)
15.990 USD
E
EKSO
0.11000
(2.33%)
4.84000 USD
M
MNKD
-0.02500
(-0.61%)
4.05000 USD
N
NEO
-0.12500
(-1.95%)
6.29000 USD
P
PRTA
-0.02500
(-0.37%)
6.68000 USD
المزيد
الأخبار المقالات

العنوان: MannKind Corp

القطاع: Healthcare
الصناعة: Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.